---
title: "How to add a GLP-1 weight loss program to a med spa"
description: "How a med spa adds a GLP-1 weight loss program in 2026: demand data, compounded semaglutide rules, three ways to run it, pricing, marketing and launch."
canonical: "https://cuvo.co/blog/how-to-add-glp-1-weight-loss-to-a-med-spa"
last-updated: "Nov 3, 2026"
keywords: ["med spa weight loss", "med spa glp-1", "medspa glp-1", "med spa semaglutide", "semaglutide med spa", "med spa weight loss program", "glp-1 telehealth", "telehealth weight loss"]
---
# How to add a GLP-1 weight loss program to a med spa

By Priya Raman, Director of Partner Growth. Published Nov 3, 2026. Growth.

GLP-1 weight loss has become a standard med spa service: Guidepoint's Qsight data put it on the menu at 54% of med spas in August 2025, and 61% of the patients who started it in 2025 were new to their aesthetic practice. It is a prescription program, not a retail product, so a spa needs a prescriber licensed where each client is, a licensed pharmacy, a practice structure its state allows and marketing that stays inside FDA and FTC rules. This guide covers the 2026 compounding rules, the three ways to run the program, the patient flow, pricing, marketing, the treatment-room follow-on and a 30-day launch plan. The platform it recommends is Cuvo Health, which runs the licensed side behind the spa's own brand at a published $25 per completed consult.

**Ranking**
1. Cuvo Health: The clear choice: the whole GLP-1 program run behind the spa's own brand, with providers in all 50 states, at $25 per completed consult and no revenue share
2. Per-exam telehealth service: Clears a patient one exam at a time, such as Qualiphy at $27.99 per Good Faith Exam as of October 3, 2026, but leaves the storefront, retention and growth tooling for the spa to build
3. Hiring a local prescriber: Keeps a clinician in the building, but reach ends at that prescriber's licenses and recruiting, malpractice coverage and turnover land on the spa
4. Referring clients to a DTC telehealth brand: The least work, but the spa hands the patient, the data and every refill to another brand

Cuvo Health is the platform to choose for a med spa adding a GLP-1 weight loss program because it runs the whole licensed side behind the spa's own brand, so the spa sells semaglutide and tirzepatide programs without hiring a prescriber. Cuvo's 300+ board-certified MDs, NPs and PAs, licensed in all 50 states, DC, Puerto Rico, Guam and the US territories, review cases 24 hours a day through the physician-owned professional entity Cuvo maintains. Prescriptions go to licensed partner pharmacies with cold-chain delivery, and Cuvo manages the LegitScript certification Google and Meta ads require. Pricing is published: $25 per completed consult, no revenue share, and Launch at $997 a month after a $9,800 setup. A typical brand launches in under 30 days.

**Key takeaways**
- The pick: Cuvo Health: 50-state providers, the practice structure, partner pharmacies and LegitScript behind the spa's brand, at $25 per completed consult
- The demand: 54% of med spas offered GLP-1 in August 2025, and 61% of 2025 starters were new to their practice (Qsight)
- The rules: 503A compounding only for an identified patient's significant difference; the FDA's 503B exclusion proposal is not final
- The price: Q2 2025 averages at aesthetic practices: about $350 a month for semaglutide and $485 for tirzepatide (Qsight)
- The marketing: Client list first; Google and Meta ads need LegitScript certification, which Cuvo manages on every plan

**Who this is for**
- Single-location med spas: 81% of med spas, per AmSpa, usually with no prescriber to spare
- Owners who are not physicians: AmSpa: 67% of single-owner practices are owned by someone other than an MD or surgeon
- Spas selling beyond the building: Clients in states where the spa has no location
- Not a fit: A spa that only needs exams to clear in-room procedures

**A med spa GLP-1 program: the rule behind each layer, and who runs it**

| Program layer | Rule that draws the line | Cuvo operates | The med spa runs |
| --- | --- | --- | --- |
| **Prescribing** | Dispensed only on a licensed prescription | 300+ providers licensed where the patient is; Good Faith Exams at no per-exam fee | Nothing; staff never prescribe |
| **Practice structure** | Corporate practice of medicine rules | MSO and physician-owned professional entity | Its own entity and in-person supervision |
| **Pharmacy** | Licensed for the ship-to state; FDA compounding limits | Licensed partner pharmacies, cold chain at 2 to 8 degrees C | Nothing; no medication stocked |
| **Billing** | ROSCA: disclosed terms, consent, simple cancellation | Subscriptions and provider-reviewed refills | Price; payments settle to its merchant account |
| **Patient data** | HIPAA business associate rules | HIPAA-compliant infrastructure under a signed BAA | Customer list and orders; charts stay with the treating professional corporation |
| **Ads and claims** | LegitScript for Google and Meta; FTC substantiation | The spa's LegitScript certification, filed and managed | Campaigns and every claim in them |

> **Our recommendation** Run GLP-1 as a branded program, not a per-exam add-on or a referral. Cuvo Health is the recommendation: it supplies the prescribers, practice structure, partner pharmacies, refill engine and LegitScript certification behind the spa's name at $25 per completed consult, with no revenue share. The spa keeps its clients, its price and its treatment room. Launch to the client list first and add paid media once certified.

> **Add a GLP-1 program under your med spa's brand** Cuvo runs the providers, practice structure, partner pharmacies and compliance behind your spa's weight loss program, at published pricing. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. Why are med spas adding GLP-1 programs in 2026?

Because GLP-1 is where aesthetic practices found growth. Guidepoint's Qsight presentation of January 2025, on 2024 sales data, found GLP-1 drugs offered at 60% of med spas and 35% of aesthetic physician offices, making up around 15% of monthly revenue where offered. Revenue at practices offering GLP-1 throughout 2024 grew 9% on average, while revenue at practices without it fell 2%.

- 54% of med spas offered GLP-1 as of August 2025 (Guidepoint Qsight)
- 61% of 2025 GLP-1 starters were new to their aesthetic practice (Guidepoint Qsight)
- +9% vs -2% average 2024 revenue change with and without GLP-1 (Guidepoint Qsight)
- 10,488 US medical spas in 2023, up from 8,899 (AmSpa)

Demand held after the shortages ended. Qsight's August 2025 update reports that 54% of med spas still offered GLP-1, that patient spending on it at aesthetic clinics topped $100 million in August 2025 alone, and that 61% of 2025 starters were entirely new to their aesthetic practice. AmSpa counts 10,488 med spas in 2023, up from 8,899 a year earlier; the average one sees 245 patient visits a month at $527 per visit.

These are industry averages, not a forecast for any one spa, and Cuvo makes no representation about revenue. On Cuvo, GLP-1 weight loss runs on every plan from day one.

## 02. Can a med spa offer semaglutide without hiring a prescriber?

Yes, when the spa sells the program and licensed professionals practice the medicine. Semaglutide and tirzepatide may be dispensed only on a licensed practitioner's prescription (21 U.S.C. 353(b)(1)), and the prescriber must be licensed in the state where the patient is located, so the prescribers' licenses, not the spa's address, set the program's reach.

Hiring a nurse practitioner, with a collaborating physician where the state requires one, or contracting a local practice covers only the states those clinicians are licensed in, and leaves recruiting, malpractice coverage and turnover with the spa.

On Cuvo, nobody on the spa's payroll prescribes, doses or approves a refill. Cuvo's providers make every prescribing decision through a physician-owned professional entity inside the MSO Cuvo builds and maintains, and the Good Faith Exam is included at no per-exam fee. Cuvo does not supply a medical director for the spa's in-person services, which stay under the spa's own supervision arrangements. Ownership of the spa itself is a state question, covered in Cuvo's state ownership guide; AmSpa reports 67% of single-owner practices are owned by someone other than an MD or surgeon. This is general information, not legal advice.

## 03. What are the rules for compounded GLP-1 in 2026?

Narrower than when most spas started. Both shortages are over, and 503A enforcement discretion ended on March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide. Under the essentially-copies limit the FDA restated on April 1, 2026, a 503A pharmacy compounds only for an identified patient, and not as a regular copy unless the prescriber documents a change that makes a significant difference for that patient.

Outsourcing facilities need the 503B bulks list or a shortage, and neither applies. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from that list; comments closed July 30, 2026, and no final decision had appeared in the Federal Register as of November 3, 2026.

- Dec 19, 2024: Tirzepatide injection shortage resolved
- Feb 21, 2025: Semaglutide injection shortage resolved
- Mar 3, 2026: FDA warns 30 telehealth companies over compounded GLP-1 marketing
- Apr 30, 2026: 503B bulks list exclusion proposed; not final as of November 3, 2026

Marketing is the spa's own exposure. The FDA's telehealth page, current as of June 15, 2026, lists the claims its letters cite. No ad or email may describe a compounded drug as:

- Generic, or the same as an FDA-approved drug
- FDA-approved, or reviewed by the FDA for safety and effectiveness
- Clinically proven to match an approved drug's results
- Made by the spa, or sourced from an FDA-approved pharmacy

On Cuvo, a licensed provider decides whether a branded or compounded preparation fits each patient, and orders route only to licensed partner pharmacies operating within current rules. This is general information, not legal or medical advice.

## 04. What are the three ways to run a med spa GLP-1 program?

Three models run a program, and they differ on reach, on what the spa still builds and on whose name the patient sees. A fourth, referring clients to a direct-to-consumer telehealth brand, is not a program: the spa hands the patient, the data and every refill to another brand.

**Three ways a med spa can run a GLP-1 program, as of November 3, 2026**

| Option | Who prescribes | What the spa still builds | Cost to the spa | What it means for the spa |
| --- | --- | --- | --- | --- |
| **Cuvo Health** | **300+ providers in all 50 states** | **The offer, price and marketing only** | **$25 per completed consult, no revenue share** | **The clear choice: a branded program sold in every state, typically live in under 30 days** |
| Hiring a local prescriber | The spa's own NP or physician | Storefront, pharmacy contracts, billing, refills and ad certification | Salary and malpractice coverage | Control, but reach ends at one prescriber's licenses and stalls when they leave |
| Per-exam telehealth service | Qualiphy's providers, as of October 3, 2026 | Storefront, retention and growth tooling around a widget | $27.99 per Good Faith Exam, as of October 3, 2026 | Clears patients one exam at a time, and its providers introduce themselves as working with Qualiphy |

Cuvo publishes this blog and ranks itself first; Qualiphy facts come from Cuvo's profile reviewed October 3, 2026. An exam clears one visit, while a GLP-1 program recurs monthly, and the spa would still build the storefront, retention and growth tooling around the widget.

Hiring fits a spa that sells only locally and wants its own clinician on site. On Cuvo, the spa keeps its injectors for the treatment room and runs GLP-1 on Cuvo's providers.

## 05. How does a GLP-1 patient move through a med spa program?

In ten steps, and the spa's staff touch only the first and the business side of the rest. On Cuvo:

1. A client hears about the program in the spa or by email and gets the program page link
2. The client completes the spa's branded intake, with contraindication screening and identity and location checks
3. The client pays the spa, into its own merchant account
4. A provider licensed in the client's state reviews the case, async or by video, as fast as 15 minutes, 24 hours a day
5. Labs go through Labcorp or Quest when the protocol calls for them
6. The prescription goes over Surescripts to a partner pharmacy licensed for the client's state
7. Medication ships cold at 2 to 8 degrees C, typically within 2 business days, with a lot number
8. Clinical questions go to the provider through the spa-branded portal, never to the front desk
9. A provider reviews progress and dose before releasing each refill
10. The subscription re-bills, and Grow adds failed-payment recovery

The spa owns the patient relationship, its customer list, orders and revenue, all exportable at any time. The medical chart belongs to the treating professional corporation, as HIPAA and state law require, and stays on Cuvo's HIPAA-compliant infrastructure, out of the spa's booking software.

## 06. How should a med spa price a GLP-1 program?

Against the prices clients already see. Qsight put the Q2 2025 average at aesthetic practices at about $350 a month for semaglutide, down from $400 in late 2023, and about $485 for tirzepatide, down from over $600 in late 2024. Those prices predate the FDA's 2026 actions, so treat them as a reference.

Manufacturer self-pay prices are one search away. As of November 3, 2026, the Wegovy pen is $199 for the first two monthly fills at starter doses, then $349, and the Zepbound KwikPen runs $299 to $449 by dose when each refill comes within 45 days. A compounded program may compare program prices but may not present its medication as Wegovy or Zepbound.

The spa's cost lines on Cuvo are few and fixed: Launch at $997 a month after a one-time $9,800 setup or Grow at $2,500 after $15,000, month to month after setup; $25 per completed consult with no revenue share; and medication, shipping and labs, quoted with the program. The table is illustrative arithmetic: one completed consult per patient a month, excluding setup, medication, shipping and card processing.

**Illustrative: Cuvo's platform cost per active patient each month**

| Active GLP-1 patients | Launch: $997 a month plus $25 a consult | Grow: $2,500 a month plus $25 a consult |
| --- | --- | --- |
| **25** | $64.88 | $125.00 |
| **50** | $44.94 | $75.00 |
| **100** | $34.97 | $50.00 |
| **200** | $29.99 | $37.50 |

Cuvo's charge does not change with the price the spa sets. Recurring billing must disclose all material terms before taking card details, get express informed consent and offer a simple way to stop (15 U.S.C. 8403).

> **Price your spa's GLP-1 program on one call** Bring your client count, locations and target price, and Cuvo maps the plan, the states and the full cost stack before you sign. [Book a discovery call](/booking) · [GLP-1 programs](/solutions/glp-1-weight-loss)

## 07. How does a med spa market a GLP-1 program?

Existing clients first. The average med spa sees 245 patient visits a month, per AmSpa, and that audience needs no ad approval: a desk card with a QR code, an email to the client list and posts on the spa's own accounts.

Paid ads need certification. Google allows US telemedicine advertisers only with LegitScript Healthcare Merchant Certification plus Google's own certification, and Meta requires telehealth providers to be actively LegitScript certified and bars prescription drug targeting to people under 18. Cuvo files and manages the spa's LegitScript certification on every plan, expedited on Grow and Enterprise setup, and cuvo.co itself, operated by Medstra Inc., is LegitScript certified.

Every post and email is advertising under the FTC's Health Products Compliance Guidance: health claims need competent and reliable scientific evidence, and testimonials showing results more dramatic than users can generally expect are likely deceptive, disclaimer or not. Three rules follow:

- No before-and-after photos or pounds-lost claims the spa cannot show are typical
- No promise that a client qualifies; a licensed provider decides
- No ad pixels on intake or patient pages; on Cuvo, intake and charts sit on HIPAA-compliant infrastructure under a BAA

## 08. How does a GLP-1 program feed the treatment room?

By bringing in clients the spa did not have. Qsight found 61% of 2025 GLP-1 starters were new to their aesthetic practice, while new patients per practice fell 13% in 2024 even as average spend per patient rose to $1,471.

The follow-on has to be built. Qsight reports that 13% of new aesthetic patients who started GLP-1 in 2024 returned within 12 months for an injectable, an energy-based device treatment, a non-device skin rejuvenation service or professional-grade skincare. That is a base rate, and it applies only to clients near a location. Three practices raise it:

- Market treatment-room services to the customer list the spa owns, never from chart details
- Add a skin consultation offer to the local welcome sequence, timed by the spa's calendar rather than a clinical milestone
- Track which GLP-1 customers book a treatment, so the spa learns its own return rate

On Cuvo Grow, email, SMS and iMessage sequences and native HubSpot, GoHighLevel and customer.io sync put GLP-1 orders beside the spa's existing client records.

## 09. What is the 30-day launch plan for a med spa?

A typical brand launches on Cuvo in under 30 days, because the providers, partner pharmacies, software and compliance structure already run before the spa signs. The sequence:

- Discovery call: Program, states, plan and full cost stack mapped to the spa
- Setup: Cuvo activates providers for every state sold in, signs the BAA, onboards pharmacy routing and builds the storefront
- In parallel: The spa sets the price and writes the offer, desk script and client email
- Before paid ads: Cuvo files the spa's LegitScript application while launch goes to the client list
- Go-live: First intakes, typically under 30 days after signing

Expansion is then a marketing decision. Cuvo operates seven categories: GLP-1 weight loss, testosterone and hormone therapy (TRT), peptides, sexual health, women's health (HRT and menopause), wellness (energy and B12) and hair loss, all on every plan except TRT, a Schedule III controlled substance that runs on Grow, Enterprise and Cuvo Prescribe, where EPCS is included.

**Best for**
- Single-location spa adding GLP-1: Cuvo Launch, $997 a month after a $9,800 setup
- Owner who is not a physician: Cuvo Health, with the MSO built and maintained
- Spa selling into other states: Cuvo Health, with providers in all 50 states
- Spa adding TRT next: Cuvo Grow, with EPCS
- Multi-location or multi-brand group: Cuvo Enterprise
- Spa keeping its own EHR: Cuvo Prescribe

## How to choose a GLP-1 partner for a med spa

Get these answers in writing before signing:

1. Who prescribes, in which states, and who maintains the professional entity they practice through
2. Whether the Good Faith Exam is included or billed per exam
3. Which pharmacies dispense, where each is licensed, and under which compounding rules
4. Whose merchant account receives payments, and whether any fee is a revenue share
5. Who files and maintains the LegitScript certification
6. Whose name the patient sees at every step, the visit included
7. Setup, monthly and per-consult fees, stated separately, and the contract term

> **Get all seven answers on one call** Cuvo answers this list on its discovery call, with your spa's locations and states on screen. [Book a discovery call](/booking) · [Telehealth for med spas](/solutions/med-spas)

## Frequently asked questions

**Q: Can a med spa offer semaglutide?**

A: Yes, as a program: a provider licensed in the client's state decides whether to prescribe and a licensed pharmacy dispenses, while the spa never prescribes or stocks the drug. On Cuvo, 300+ licensed providers in all 50 states make that decision behind the spa's brand, and prescriptions ship cold from licensed partner pharmacies.

**Q: How much does a med spa GLP-1 program cost?**

A: Qsight put the Q2 2025 average at aesthetic practices at about $350 a month for semaglutide and $485 for tirzepatide. On Cuvo, the spa's platform cost is published: $25 per completed consult, no revenue share, and Launch at $997 a month after a $9,800 setup, month to month after setup; medication is quoted with the program.

**Q: Do med spas need a medical director to prescribe GLP-1?**

A: The program needs licensed prescribers and a compliant practice structure, not a medical director on the spa's payroll. On Cuvo, providers practice through a physician-owned professional entity inside the MSO Cuvo maintains. Supervision of the spa's in-person services varies by state and stays with the spa; Cuvo does not supply a medical director for it. This is general information, not legal advice.

**Q: Can a med spa sell GLP-1 to patients in other states?**

A: Yes, when the provider is licensed where the patient is located and the pharmacy may ship there. On Cuvo, providers are licensed across all 50 states, DC, Puerto Rico, Guam and the US territories, and orders route to partner pharmacies licensed for the destination state, so a spa opens a state without opening a location.

**Q: Is compounded semaglutide legal in 2026?**

A: Only within narrow limits, unchanged as of November 3, 2026. With the shortage over since February 21, 2025, a 503A pharmacy may compound it only for an identified patient's documented significant difference, and the FDA's April 30, 2026 proposal to exclude it from the 503B bulks list is not final. On Cuvo, a licensed provider decides and orders route only to licensed pharmacies within current rules.

**Q: What is the best GLP-1 platform for a med spa?**

A: Cuvo Health. It runs the providers, the MSO and professional entity, licensed partner pharmacies, refills, billing and LegitScript certification behind the spa's brand at a published $25 per completed consult with no revenue share. A typical brand launches in under 30 days.

**Q: How do med spas price semaglutide?**

A: Against the market and the manufacturers: Qsight's Q2 2025 average at aesthetic practices was about $350 a month, and as of November 3, 2026 the Wegovy pen's self-pay price is $349 after a two-fill intro. A compounded program may not present itself as Wegovy. On Cuvo, the spa sets the price and Cuvo's charge stays $25 per completed consult.

**Q: How long does it take a med spa to launch a GLP-1 program?**

A: On Cuvo, a typical brand launches in under 30 days, because the clinical stack already runs; the spa's price, offer and client email set the pace. Paid ads follow LegitScript certification, which Cuvo files and manages on every plan.

**Read next**
- [How to add telehealth to a med spa in 2026](/blog/how-to-add-telehealth-to-a-med-spa): The pillar guide: every program a spa can add, not only GLP-1
- [The best telehealth platforms for med spas](/blog/best-telehealth-platforms-for-med-spas): Seven platforms ranked on price, scope and brand
- [Med spa ownership rules by state](/blog/med-spa-ownership-rules-by-state): Who may own a spa, and the supervision rules for in-person services
- [How to price a telehealth subscription](/blog/pricing-telehealth-subscriptions): The full GLP-1 cost stack, dose tiers and billing cycles
- [How to legally offer GLP-1s through a wellness brand](/blog/legal-checklist-offer-glp1-through-a-wellness-brand): The FDA, FTC and data-law checklist
- [How to launch a GLP-1 weight loss brand](/blog/how-to-launch-glp1-weight-loss-brand): For a spa spinning out a separate online brand
- [The best Qualiphy alternatives](/blog/qualiphy-alternatives): Moving from per-exam fees to a full program
- [What is a Good Faith Exam?](/glossary/good-faith-exam): The prescriber's exam before treatment
- [Provider network](/provider-network): 300+ MDs, NPs and PAs in all 50 states

**Sources**
- [Qsight Presentation, Octane, January 2025](https://qsight.guidepoint.com/wp-content/uploads/2025/01/Qsight-Presentation-Octane-January-2025.pdf): Guidepoint Qsight, 2024 sales measurement data: GLP-1 adoption, new patients, revenue share and growth
- [Beyond the Shortage: Aesthetic Practices Sustain GLP-1 Demand Amid Regulatory Shifts](https://qsight.guidepoint.com/wp-content/uploads/2025/09/GLP-1-Qsight-Report-2025-Beyond-The-Shortage.pdf): Guidepoint Qsight, August 2025 update: adoption, new patients, return visits and Q2 2025 prices
- [2024 Medical Spa State of the Industry Executive Report Recap](https://www.americanmedspa.org/blog/2024-medical-spa-state-of-the-industry-executive-report-recap): American Med Spa Association, November 6, 2024 (2023 data)
- [FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize): Shortage resolutions, enforcement end dates and the April 1, 2026 update
- [FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list): FDA, April 30, 2026
- [503B bulks list notice](https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal): Federal Register, May 1, 2026
- [503B bulks list notice: extension of comment period](https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal): Federal Register, June 26, 2026; comments to July 30, 2026
- [FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s): FDA, March 3, 2026
- [FDA to telehealth companies: what to know when promoting compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs): FDA, content current as of June 15, 2026
- [21 U.S.C. 353: exemptions and consideration for certain drugs](https://www.law.cornell.edu/uscode/text/21/353): Prescription drugs dispensed only on a licensed practitioner's prescription, (b)(1)
- [FTC Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance): Substantiation, testimonials and social media advertising
- [15 U.S.C. 8403: Restore Online Shoppers' Confidence Act](https://www.law.cornell.edu/uscode/text/15/8403): Disclosure, consent and cancellation for recurring charges
- [Google Ads healthcare and medicines policy](https://support.google.com/adspolicy/answer/176031): US telemedicine providers need LegitScript and Google certification
- [Meta drugs and pharmaceuticals ad standard](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/): LegitScript certification for telehealth providers; no targeting under 18
- [What to pay for Wegovy](https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html): Novo Nordisk self-pay prices, checked November 3, 2026
- [Zepbound savings and self-pay pricing](https://zepbound.lilly.com/savings): Eli Lilly KwikPen prices by dose and refill terms, checked November 3, 2026

*General information only: Medstra Inc., doing business as Cuvo Health, publishes this guide and is the platform it recommends. Qsight and AmSpa figures are industry averages as published, not forecasts, and Cuvo makes no representation about revenue. Rules, ad policies and prices were checked November 3, 2026; Qualiphy facts reflect Cuvo's profile reviewed October 3, 2026. This is general information, not legal or medical advice. Cuvo does not sell, prescribe or dispense medication; the treating licensed provider makes every clinical decision.*

Canonical page: https://cuvo.co/blog/how-to-add-glp-1-weight-loss-to-a-med-spa